Corcept to resubmit relacorilant application to FDA

Corcept plans to resubmit its NDA for relacorilant to the FDA in the coming weeks after completing additional analyses requested in a complete response letter. The company also reported Q1 2026 revenue of about $165 million, down from the $186 million consensus but up 4.9% year over year, and raised full-year revenue guidance to $950 million-$1.05 billion. H.C. Wainwright lifted its price target to $75 from $65 while keeping a Buy rating.

Analysis

CORT’s setup is less about the resubmission headline and more about de-risking a binary regulatory overhang into a measurable 6-month catalyst path. Once the filing is accepted, the market can start discounting a PDUFA date and, more importantly, a second approved cortisol-modulating revenue leg that could materially improve the durability of the franchise beyond Korlym. That matters because specialty pharma multiple expansion tends to happen when investors can underwrite a multi-product cash flow stream rather than a single-asset story.

The second-order winner is likely not a direct competitor but the ecosystem around endocrine specialty care: if relacorilant gains traction, it strengthens the broader cortisol-modulation category and increases physician comfort with the mechanism, which can expand total addressable prescribing rather than just steal share. The loser is any short thesis predicated on CORT as a one-product company; with Lifyorli already expanding the revenue base, the balance of evidence suggests the market is underestimating the optionality of an approved pipeline plus commercial execution.

That said, the stock’s move already bakes in a decent amount of optimism, and the cleanest near-term risk is procedural rather than scientific: a fresh FDA request for additional analyses, labeling friction, or another delay would compress the multiple quickly because the catalyst is time-sensitive. Over the next 1-3 months, the stock should trade on submission/acceptance milestones; over 6-9 months, the real inflection is whether the company can sustain top-line acceleration without margin compression from launch spend and SG&A.

The contrarian angle is that the market may be overweighting regulatory momentum and underweighting execution risk. If the resubmission gets accepted cleanly, the path of least resistance is higher; if not, a 15-25% drawdown is plausible because the stock has already rerated on expectation rather than earnings power. In other words, this is a good story, but not yet a cheap one, so timing matters more than conviction alone.

Key Decisions for Investors

• Hold/accumulate CORT on a pullback only, targeting entries on any 8-12% post-news retracement; risk/reward is best if you can buy before FDA acceptance rather than after it is confirmed.
• Express a catalyst trade with CORT Jan/Feb call spreads or long-dated calls into the expected PDUFA window; upside is a rerating on acceptance, while premium paid should be limited because the market is already leaning positive.
• For risk control, pair a long CORT with a small short in a higher-multiple, single-asset biotech peer to isolate regulatory de-risking from sector beta; use this only if you can find a name with similar headline sensitivity but weaker commercial base.
• Trim or hedge if CORT closes above a near-term valuation threshold following resubmission acceptance; the stock likely shifts from catalyst-driven to execution-driven, reducing asymmetry.
• Do not chase aggressively here unless the filing is accepted quickly; if the FDA pushes back again, expect the stock to reprice sharply lower over days, not months.